# SEC 8-K Summary: Clover Health Investments, Corp. On June 9, 2026, Clover Health received a significant favorable court ruling when the U.S. District Court for the Southern District of Georgia granted summary judgment to overturn its 2026 Star Rating of 3.5 Stars for its primary PPO plan (Contract H5141), which covers over 97% of the company's members. Following the court order, CMS recalculated Clover's 2026 Star Rating upward to 4.5 Stars, a material improvement that will positively impact Payment Year 2027 reimbursement rates and plan competitiveness. The higher star rating enhances the company's ability to attract and retain members and improves financial performance, as star ratings directly affect Medicare Advantage plan payments and member perception. The company's HMO plan (Contract H8010) retained its previously-reported 4.0 Star Rating and was not subject to litigation.

# Summary of Taboola.com Ltd. 8-K Filing (June 9, 2026) Taboola.com held its Annual General Meeting of Shareholders on June 9, 2026, and shareholders approved all five proposals with substantial majorities, including the re-election of two Class II directors, an advisory vote on executive compensation, a new compensation policy for executives and directors, CEO compensation terms, and the re-appointment of Kost, Forer, Gabbay & Kasierer (EY) as independent auditor. The voting results show strong shareholder support, with particularly overwhelming approval for the auditor re-appointment (99.6% in favor). This routine governance approval provides continuity in leadership and auditing arrangements, with no material adverse impacts indicated; however, the significant "against" votes on CEO compensation (approximately 9.7% opposition) may warrant attention to shareholder concerns regarding executive pay.

# Virgin Galactic Holdings, Inc. (SPCE) - 8-K Summary Virgin Galactic redeemed $30.5 million in principal of its 9.80% First Lien Notes due 2028 by issuing 6,734,960 shares of common stock on June 10, 2026, reducing debt-related cash interest obligations as part of its capital management strategy ahead of commercial operations in Q4 2026. Following the redemption, approximately $172 million in First Lien Notes remain outstanding with no principal payment due until March 31, 2028. The redemption represents a strategic debt-for-equity swap that improves near-term cash flow but dilutes existing shareholders through the issuance of new shares priced at prevailing market rates. This transaction demonstrates management's focus on strengthening the balance sheet and liquidity position before launching commercial spaceflight operations, though investors should note the meaningful equity dilution involved in this refinancing approach.

# Summary of SIGA Technologies 8-K Filing SIGA Technologies held its 2026 annual stockholder meeting on June 9, 2026, with strong shareholder participation (87.05% attendance). Key outcomes included the election of all eight director nominees, ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of a significant stock incentive plan amendment increasing authorized shares by 6.5 million (from 8.5 million to 15 million total shares). The advisory vote on executive compensation also passed, though with somewhat lower support (48.7 million vs. 2.4 million votes against). The increased share authorization signals the company's intent to expand equity-based compensation, which could dilute existing shareholders but enables greater flexibility for future employee retention and acquisition opportunities.

# Summary of Butler National Corporation 8-K Filing On June 4, 2026, Butler National Corporation's Compensation Committee approved a $90,000 annual salary increase for Executive Chairman Jeffrey D. Yowell, raising his total compensation to $340,000 per year effective June 1, 2026. This increase represents a 36% boost to his base compensation and brings his total pay to a level that includes the standard $90,000 paid to all non-employee directors. Mr. Yowell appropriately recused himself from the Committee's discussion and voting on the matter. For investors, this filing indicates routine executive compensation decisions at the company, though the substantial raise may warrant scrutiny regarding alignment with company performance and shareholder interests.

# B&G Foods 8-K Summary On June 10, 2026, B&G Foods closed a private offering of $475.0 million in 11.00% senior notes due 2031 at 97.67% of face value, creating a direct financial obligation to investors. The company intends to use net proceeds along with revolving credit borrowings and cash on hand to redeem its entire $509.3 million outstanding 5.25% senior notes due 2027, effectively refinancing maturing debt at a significantly higher interest rate. This refinancing increases the company's annual debt service costs by approximately $29.1 million annually (the difference between 11.00% and 5.25% interest rates), which will pressure near-term profitability and cash flow. The new notes are unsecured senior debt with standard restrictive covenants limiting dividends, asset sales, and additional borrowing, and they are effectively junior to any secured debt, giving secured creditors priority in a default scenario.

# Aquestive Therapeutics 8-K Summary Aquestive Therapeutics held its 2026 Annual Meeting of Stockholders on June 10, 2026, where shareholders approved all three matters submitted for vote with strong support. The three Class II director nominees—Gregory B. Brown, John S. Cochran, and Abigail L. Jenkins—were elected to three-year terms, with Brown and Jenkins receiving overwhelming approval (>94% of votes cast). Shareholders also approved executive compensation on a non-binding advisory basis with 92% support, and ratified KPMG LLP as the independent auditor for fiscal year 2026 with 98.8% approval. These routine governance actions indicate strong shareholder confidence and carry no material adverse implications for investors.

# Prelude Therapeutics 8-K Summary Prelude Therapeutics held its 2026 Annual Meeting of Stockholders on June 9, 2026, at which shareholders approved all four proposals with strong majorities. The three Class III director nominees—Krishna Vaddi, Paul Scherer, and Katina Dorton—were elected to three-year terms, with over 98% approval for Vaddi and Dorton and approximately 94% for Scherer. Shareholders also ratified Ernst & Young LLP as the independent auditor for fiscal year 2026 and approved executive compensation with over 99% support, while voting to hold advisory compensation votes annually. **Investor Impact:** This routine governance filing indicates stable leadership continuity and strong shareholder support for management's compensation practices, with no material business changes or concerns raised that would impact investors.

# Incannex Healthcare Inc. - Form 8-K Summary This Form 8-K filing from Incannex Healthcare Inc. (NASDAQ: IXHL) contains only a Regulation FD disclosure filed on June 10, 2026, with the substantive details relegated to an attached press release (Exhibit 99.1) that is not included in this document. Without access to the actual press release content, the specific material event cannot be determined from the 8-K form itself. The filing indicates the company is an emerging growth company incorporated in Delaware with its principal executive offices in Melbourne, Australia. Investors seeking details about what drove this disclosure should review the accompanying press release to understand any material developments, business updates, or significant announcements.

# Forward Industries, Inc. Form 8-K Summary Forward Industries, Inc. announced on June 9, 2026 that it made an indicative, non-binding proposal on June 1, 2026 to acquire all issued and to-be-issued share capital of Brera Holdings PLC in an all-stock transaction. The company emphasizes that no certainty exists regarding whether a formal offer will materialize, and it will not disclose additional transaction details outside of subsequent public announcements. The filing highlights significant forward-looking risks including volatility in cryptocurrency prices (particularly Solana), regulatory uncertainty surrounding digital assets, tax treatment ambiguity, and potential correlation between Forward Industries' stock price and its cryptocurrency holdings. Investors should note this represents an early, exploratory phase with substantial execution risk, and the all-stock structure means existing shareholders may face significant dilution if the acquisition proceeds.

# Summary of Iovance Biotherapeutics, Inc. 8-K Filing (June 4, 2026) Iovance Biotherapeutics reported two material events: (1) the Australian Therapeutic Goods Administration granted marketing authorization for Amtagvi® for previously treated advanced melanoma, representing a significant regulatory milestone for the company's lead immunotherapy product, and (2) stockholders approved all seven proposals at the annual meeting held June 10, 2026, with 74% shareholder participation, including board director elections, executive compensation, auditor ratification, and notably an increase in authorized common stock from 500 million to 650 million shares and an additional 1 million shares for the employee stock purchase plan. The Australian approval expands the company's commercial footprint for Amtagvi®, which should support revenue growth and market penetration in the Asia-Pacific region. The increased authorized shares provide management greater flexibility for future financing, acquisitions, or employee equity programs, though the substantial 37.2% opposition vote on the share authorization proposal suggests some investor concern regarding potential dilution.

# Allbirds, Inc. (BIRD) 8-K Summary Allbirds completed the initial closing of its senior secured convertible notes financing on June 4, 2026, selling $5.0 million in principal amount under a previously announced $50.0 million facility. The offering was conducted as a private placement under Rule 506(b), with $41.75 million remaining available for future drawdowns at the discretion of note holders. The company intends to use the net proceeds for general corporate purposes and working capital, indicating ongoing liquidity needs to support operations. This financing structure—convertible debt rather than equity—provides the company with near-term capital while deferring dilution to existing shareholders until potential conversion, though the availability of an additional $41.75 million suggests investors retain flexibility to provide additional capital depending on company performance.

# CS Disco, Inc. (LAW) - 8-K Summary CS Disco held its 2026 Annual Meeting of Stockholders on June 10, 2026, with routine corporate governance matters on the agenda. Stockholders elected two Class II directors—James Offerdahl and Toby Williams—to serve until the 2029 Annual Meeting, with Offerdahl receiving 38.6 million votes for and Toby Williams receiving 42.8 million votes for. Additionally, shareholders overwhelmingly ratified Ernst & Young LLP as the company's independent auditor for fiscal year 2026, with 55.4 million votes in favor versus only 428,849 votes against. This filing reflects standard annual governance proceedings with strong shareholder approval across all proposals and no material changes to the company's operations or financial position.

# Summary of Trump Media & Technology Group Corp. 8-K Filing (June 10, 2026) Trump Media & Technology Group Corp. (TMTG) announced a merger update with TAE Technologies, Inc., a fusion energy company, through a press release issued on June 10, 2026. The company intends to file a Form S-4 registration statement with the SEC to register TMTG common stock to be issued in connection with the proposed transaction, which will include a proxy statement/prospectus and consent solicitation statement requiring shareholder approval. This merger represents a significant strategic shift for TMTG, moving from a media company into the advanced fusion energy sector, exposing investors to the substantial uncertainties and technical risks associated with commercializing fusion technology. Investors should carefully review all SEC filings and the proxy materials when available, as the transaction involves material forward-looking statements subject to numerous risks that could cause actual results to differ materially from expectations.

# Summary of Mountain Lake Acquisition Corp. 8-K Filing Mountain Lake Acquisition Corp. announced on June 10, 2026, that it has postponed its extraordinary general meeting of shareholders from June 16 to June 16, 2026 (with a time adjustment to 10:00 a.m. Eastern Time) to allow additional time to complete its business combination with Avalanche Treasury Corporation. The key proposal at the meeting is to approve an extension of the company's deadline to consummate an initial business combination from June 16, 2026 to September 16, 2026. Notably, shareholders had already approved the proposed merger with Avalanche Treasury Corporation on June 4, 2026, and the company indicated it expects to complete the business combination promptly once all closing conditions are satisfied or waived. The filing carries typical forward-looking statement disclaimers regarding execution risks and timing uncertainties inherent to SPAC transactions.

# Stitch Fix, Inc. (SFIX) 8-K Summary Stitch Fix announced its third quarter fiscal 2026 financial results (ended May 2, 2026) on June 10, 2026. The company held a conference call the same day to discuss Q3 performance with investors. No material operational changes, acquisitions, divestitures, or governance actions were disclosed in this filing. The earnings announcement itself is contained in the press release (Exhibit 99.1), which would provide details on revenue, profitability, and forward guidance material to investor decision-making. Investors should review the accompanying earnings release for specific financial metrics and management commentary on operational performance.

# OFS Capital Corporation 8-K Summary OFS Capital Corporation held its 2026 Annual Meeting of Stockholders on June 10, 2026, with a quorum of 8.7 million shares represented (65.2% of outstanding shares). Stockholders elected two Class II directors—Romita Shetty and Bilal Rashid—who will serve three-year terms through 2029, and ratified KPMG LLP as the independent auditor for fiscal year 2026. Both matters passed with substantial majorities, indicating strong shareholder support for the company's governance and audit arrangement. This is a routine corporate governance event with no material adverse developments or changes to the company's operational or financial status.

# Summary of Voyager Therapeutics 8-K Filing On June 9, 2026, Voyager Therapeutics, Inc. held its annual stockholder meeting and approved a significant amendment to its Certificate of Incorporation, doubling authorized common stock from 120 million to 240 million shares (and total authorized capital from 125 million to 245 million shares). This increase provides the company with substantially more flexibility for future financing, equity-based compensation, acquisitions, or strategic transactions without requiring another shareholder vote. Additionally, stockholders elected three Class II directors (James Geraghty, Steven Hyman, and Alfred Sandrock) and approved executive compensation on an advisory basis, with strong support for all proposals. Ernst & Young LLP was ratified as the company's independent auditor for fiscal 2026. **Investor Impact:** The expanded share authorization is a neutral to slightly dilutive event that gives management greater capital-raising capacity but also increases potential dilution risk to existing shareholders if heavily used. The strong shareholder votes indicate continued confidence in the company's leadership and strategy.

# SEC 8-K Summary: Mountain Lake Acquisition Corp. Mountain Lake Acquisition Corp. postponed its extraordinary general meeting of shareholders from an unspecified date to June 16, 2026, to allow additional time to complete its previously approved business combination with Avalanche Treasury Corporation. The postponement extends the deadline for shareholder approval of an Articles Extension, which would give the company until September 16, 2026 (rather than June 16, 2026) to consummate the business combination. All other meeting details—including location, record date, redemption deadline, and proposals—remain unchanged. For investors, this timing extension reduces immediate execution risk but introduces uncertainty about whether the deal will close by the new September deadline, as completion remains contingent on satisfying or waiving all conditions to the business combination.

# Quanterix Corporation (QTRX) 8-K Summary At its June 9, 2026 Annual Meeting of Stockholders, Quanterix Corporation approved three of four proposals, with stockholders electing two independent directors (William P. Donnelly and Ivana Magoveviċ-Liebisch) and ratifying KPMG LLP as the independent auditor for fiscal year 2026. An advisory vote on named executive officer compensation also passed with approximately 87.6% support. However, stockholders rejected Proposal 4, which sought to amend and extend the company's 2017 Employee, Director and Consultant Equity Incentive Plan through June 9, 2031, with only 28.7% voting in favor versus 71.0% opposed. The rejection of the equity plan amendment represents a material governance setback, signaling stockholder concern regarding equity compensation practices or dilution concerns. Investors should monitor whether management will pursue alternative equity compensation structures or return to shareholders with a revised proposal.

# Summary of Apartment Investment and Management Company 8-K Filing On June 10, 2026, Aimco held its Annual Meeting of Stockholders where shareholders voted on three routine proposals. All nine director nominees were elected with strong support (ranging from 106.7 to 106.9 million votes in favor), Grant Thornton LLP was ratified as the independent auditor, and shareholders gave advisory approval to executive compensation with approximately 99% support. This filing presents no material adverse events or material changes to the company's business; rather, it documents standard corporate governance actions with overwhelming shareholder approval, indicating continued investor confidence in management and the board's direction.

# ZoomInfo Technologies Inc. - 8-K Summary ZoomInfo Technologies Inc. announced on June 5, 2026, that its Compensation Committee approved a performance-based cash bonus opportunity for Chief Financial Officer Michael Graham O'Brien with a target award value of $500,000. The bonus will be earned based on the company's achievement of fiscal year 2026 adjusted operating income goals, with actual payouts potentially ranging from 0% to 150% of the target amount depending on performance level achievement. The Committee will determine the final payout following completion of the company's 2026 financial statements. This compensation arrangement ties executive pay directly to profitability metrics, aligning management incentives with shareholder interests and financial performance objectives.

# Summary of DeFi Development Corp. (DFDV) 8-K Filing DeFi Development Corp. announced the resignation of Parker White, its Chief Operating Officer and Chief Investment Officer, effective June 8, 2026. Under the separation agreement, White will receive $250,000 in cash payments over twelve months, acceleration of 213,272 unvested stock options, and ongoing monthly consulting fees of $8,333 for operational transition services related to the company's validators. This executive departure represents a material change in leadership structure, though the company has mitigated continuity risk by retaining White as a consultant for critical operational matters. For investors, this signals potential strategic repositioning but requires monitoring to ensure smooth validator operations and whether additional leadership changes or operational disruptions may follow.

# SEC 8-K Summary: Braemar Hotels & Resorts Inc. Braemar Hotels & Resorts Inc. announced on June 4, 2026, that its indirect subsidiaries entered into an agreement to sell three premium hospitality properties—The Ritz-Carlton Sarasota, Hotel Yountville, and Bardessono Hotel and Spa—for a combined purchase price of $437.5 million in cash. The transaction is expected to close within 20-35 days, subject to customary closing conditions and regulatory approvals. This asset sale represents a material portfolio restructuring that will provide significant liquidity to the company, though investors should note that closing remains contingent on satisfaction of customary conditions and there is no absolute assurance the transaction will complete as described.

# Summary of Tandy Leather Factory, Inc. 8-K Filing On June 9, 2026, Tandy Leather Factory held its annual stockholder meeting and implemented several significant corporate governance and compensation changes. The Board increased annual cash retainer fees for non-employee directors to $20,000 and enhanced committee fees, while also immediately accelerating the vesting of all outstanding RSUs and switching to immediate vesting for future grants, which could significantly impact executive retention and equity costs. John Gehre was appointed as the new Chairman of the Board, marking a leadership transition. All six director nominees were re-elected with substantial shareholder support, and the advisory vote on executive compensation passed decisively with approximately 90.6% approval, indicating overall investor confidence in current compensation practices despite the accelerated RSU vesting change.

# Summary of Eva Live Inc. 8-K Filing Eva Live Inc. announced on June 10, 2026, that it has signed a letter of intent to acquire Psquared, a move intended to enhance its AI-powered performance marketing platform. The acquisition targets the $1 trillion digital advertising market, positioning Eva Live to expand its technology capabilities and market reach. This is a non-binding preliminary agreement, as indicated by the "letter of intent" designation, meaning the transaction is not yet finalized and remains subject to further negotiation and due diligence. For investors, this represents a potential strategic pivot toward AI-driven marketing solutions, though the lack of financial terms disclosed and the preliminary nature of the deal warrant caution regarding execution risk and actual value creation.

# CervoMed Inc. (CRVO) 8-K Summary CervoMed Inc. entered into a securities purchase agreement on June 9, 2026, to raise approximately $10.5 million through a private placement of 3.36 million units, each comprising common stock or pre-funded warrants plus Series B and C warrants, with potential additional proceeds of up to $21.7 million if all warrants are exercised for cash. Insiders including Chairman Joshua Boger and CEO John Alam are participating for approximately 1.37 million units. The company estimates the net proceeds will fund operations into Q2 2027, supporting research and development of its clinical-stage drug candidate neflamapimod, with placement agent fees totaling approximately 6% of gross proceeds. The transaction is expected to close on or about June 11, 2026, and includes anti-dilution protections with beneficial ownership limitations between 4.99% and 19.99% for warrant holders.

# Summary of Mobix Labs, Inc. 8-K Filing (June 9, 2026) Mobix Labs announced multiple material developments, including active negotiations to acquire Vision Aerial (a company with growing revenue and backlog) via non-binding letter of intent, though no definitive agreement exists yet. The company disclosed plans to amend financing transaction documents with Kips Bay Select LP to correct technical errors without materially changing economic terms, and to file a resale registration statement for approximately 4.5 million shares. A stockholder meeting is anticipated for July 2026 to approve several proposals, including issuance of shares to Kips, removal of Class B stock restrictions, increased equity plan capacity, and authorization for future fundraising and acquisition financing. The company also reported settling two lawsuits and reducing debt by approximately $3.74 million, though it continues to seek additional capital, which could result in significant dilution to existing shareholders. **Investor Impact:** While debt reduction and potential acquisition growth are positive, investors face considerable uncertainty from the non-binding nature of the Vision Aerial deal, anticipated shareholder dilution from multiple planned equity issuances, and conditional stockholder approvals required to proceed with strategic initiatives.

# Aethlon Medical, Inc. 8-K Summary Aethlon Medical, Inc. (NASDAQ: AEMD) filed an 8-K on June 10, 2026, disclosing Q1 2026 financial results through a press release furnished under Regulation FD. The filing contains no material transactions, corporate events, or significant operational changes—it solely announces quarterly financial results. The company provided no details within the 8-K itself regarding earnings, cash position, operational metrics, or guidance, as the substantive information is contained only in the referenced press release (Exhibit 99.1). Investors should review the full press release for detailed financial performance and any material developments affecting the company's outlook.

# Clean Energy Fuels Corp. (CLNE) 8-K Summary Clean Energy Fuels Corp. held its 2026 annual stockholder meeting on June 10, 2026, where shareholders approved all three proposals with strong majorities. The company's six board nominees were elected with 97% average approval, KPMG LLP was ratified as the independent auditor with 95% support, and executive compensation was approved on an advisory basis with 91% support. These routine governance matters indicate stable shareholder confidence in the company's current leadership and management structure. The voting results show no material controversies or shareholder dissent on compensation or corporate governance practices.

# Helio Corporation 8-K Summary Helio Corporation filed an 8-K on June 10, 2026, disclosing a press release update regarding its registration status (Item 7.01 Regulation FD Disclosure). However, the actual press release content is not included in the filing itself—only a reference to Exhibit 99.1. The company explicitly noted that the furnishing of information is not an admission of materiality and undertook no obligation to update the disclosed information. As an emerging growth company, Helio has limited public trading visibility, with no securities registered under Section 12(b) of the Securities Exchange Act. **Without access to the actual press release, the specific material event and investor impact cannot be fully assessed**, though the filing suggests a potentially significant change in the company's registration status that warrants investor attention upon review of the attached press release.

# CID Holdco, Inc. (DAIC) - 8-K Summary CID Holdco announced on June 10, 2026 that it has entered into two non-binding letters of intent as part of a strategic alternatives review: a proposed $5.0 million convertible preferred stock investment from an investor and a separate transaction to sell a portion of its operating business for approximately $6.0 million in cash plus assumption of up to $3.0 million in liabilities. The investor may also provide additional funding for value-creating initiatives. These transactions remain non-binding and subject to execution of definitive agreements, stockholder approval, lender and regulatory approvals, and Nasdaq listing compliance. While the proposed capital infusion and business sale could provide liquidity and strategic direction for the financially stressed company, investors should note the significant uncertainties regarding deal completion and the dilutive impact of the convertible preferred stock on existing shareholders.

# Rafael Holdings, Inc. - 8-K Summary Rafael Holdings announced on June 10, 2026, that the last patient has completed the final 96-week study visit in its pivotal Phase 3 TransportNPC™ clinical trial evaluating Trappsol® Cyclo™ for treating Niemann-Pick Disease Type C. The company expects to release topline data from the main study cohort in the second half of 2026. This milestone represents a critical step toward potential regulatory approval, with the upcoming data release likely to be a key catalyst for investor sentiment and future development decisions.

# KIDZ AI Inc. (KIDZ) – 8-K Summary KIDZ AI Inc. held its annual stockholder meeting on June 10, 2026, and obtained approval for five material proposals that significantly expand the company's financial flexibility and governance structure. Most notably, shareholders approved increasing authorized Class B common stock to 2.5 billion shares (Proposal 1) and authorized the issuance of shares to Solana Growth Ventures LLC under an Exchange Agreement dated December 29, 2025 (Proposal 2). Additionally, shareholders approved a reverse stock split at a ratio between 1-for-2 and 1-for-50 to be determined by the board, and authorized the sale of up to 500,000 Class A shares to CEO Hui Luo at 150% of prevailing market price. All five board directors were re-elected, including CEO Hui Luo. **Investor Impact:** The substantial increase in authorized shares and approval of dilutive issuances to Solana Growth Ventures could pressure existing shareholders through equity dilution. The reverse stock split authority suggests potential compliance concerns (possibly Nasdaq listing standards), while CEO stock purchase authorization at a premium raises governance questions. These actions indicate capital-raising activities and potential financial restructuring ahead.

# SenesTech, Inc. (SNES) 8-K Summary On June 9, 2026, SenesTech held its annual stockholder meeting and approved all four proposals with strong majorities. Shareholders elected directors Jake Leach and Joshua Moss to three-year terms, endorsed executive compensation via advisory vote (90.5% in favor), and approved a 1.2 million share increase to the 2018 Equity Incentive Plan to support future equity awards. Additionally, shareholders ratified M&K CPAS, PLLC as the independent auditor for fiscal 2026. The approval of the equity plan expansion is the most material development for investors, as it provides the company flexibility for employee compensation and retention but will result in potential dilution to existing shareholders.

# Aldeyra Therapeutics 8-K Summary On June 9, 2026, Aldeyra Therapeutics held its annual stockholders meeting and appointed Darlene Deptula-Hicks as a Class III director and Audit Committee Chair, effective immediately. Ms. Deptula-Hicks, determined to be independent and qualified as an audit committee financial expert, will receive an annual director fee of $40,000 plus $7,500 for audit committee leadership, along with equity grants including 94,313 stock options vesting over three years and annual renewal grants. At the meeting, stockholders approved three routine proposals: the election of Todd C. Brady, M.D., Ph.D. as a Class III director (23.0 million votes for, 1.1 million withheld), the ratification of BDO USA, P.C. as independent auditors (43.7 million votes for), and an advisory approval of executive compensation (19.5 million votes for). These actions represent standard governance matters with no material operational, financial, or strategic changes affecting the company's business or investor position.

# USIO, Inc. (USIO) 8-K Summary On June 10, 2026, USIO held its Annual Meeting of Stockholders and amended its bylaws to implement anti-takeover provisions and comply with SEC universal proxy rules. The company elected two Class III directors (Ernesto R. Beyer and Bradley Rollins), with overwhelming shareholder approval, and ratified Withum Smith+Brown, P.C. as the independent auditor for fiscal 2026. The amended bylaws establish advance notice procedures for stockholder proposals and director nominations (90-120 days prior to annual meetings) and permit remote stockholder meetings, while explicitly noting these provisions may "defer, delay or discourage a potential acquiror" from attempting a proxy contest or takeover. **Investor Impact:** The bylaw amendments represent a defensive posture that could entrench management and raise the barrier for activist investors or acquirors seeking control. While routine governance updates were included, the emphasis on anti-takeover language and advance notice requirements may signal concern about potential M&A activity and could reduce shareholder activism flexibility going forward.

# SEC 8-K Summary: Blockchain Digital Infrastructure, Inc. Blockchain Digital Infrastructure, Inc. (NYSE American: AIB) completed a public offering on June 8, 2026, issuing 33.3 million shares at $1.65 per share, raising approximately $51.4 million in net proceeds after underwriting costs. The company granted underwriter Lucid Capital Markets a 45-day option to purchase an additional 4.9 million shares to cover over-allotments, and issued warrants to purchase 1.3 million shares at an exercise price of $1.815 per share. The company intends to use the proceeds for working capital, capital expenditures, and general corporate purposes. Notably, insiders and the company face 90-day lock-up restrictions on share issuances and stock sales, while the company is also restricted from entering variable rate financing transactions for 180 days, limiting near-term dilution risks for existing shareholders.

# enGene Therapeutics Inc. (ENGN) - 8-K Summary enGene Therapeutics held its 2026 Annual General Meeting on June 9, 2026, with strong shareholder participation of 83.89%. All four director nominees—Philip Astley-Sparke, Ronald H.W. Cooper, Dr. William Grossman, and Michael Heffernan—were elected with overwhelming support (over 99.3% approval each). The company's auditor was also reappointed with similar overwhelming approval (99.97% of votes cast). These results indicate strong investor confidence in the company's leadership and governance structure, with no material opposition to management's slate of directors or audit firm selection.

# Veritone, Inc. (VERI) - 8-K Summary Veritone announced a significant restructuring plan initiated on June 10, 2026, involving a workforce reduction of at least 25% and reductions in third-party operating costs aimed at cutting up to 30% of annual operating expenses. The restructuring will be implemented in phased phases with substantial completion expected by late July 2026, though the company cannot currently estimate the total costs associated with severance payments, exit costs, and benefit continuation. Upon completion in Q3 2026, management expects to achieve an annualized cost reduction of 30% compared to the trailing twelve-month period ended March 31, 2026. While this restructuring signals management's commitment to improving operational efficiency and preserving cash, investors should monitor Q3 results for the actual costs incurred and verify whether the company achieves its targeted expense reductions, as the company has provided limited financial detail at this stage.

# InMed Pharmaceuticals Inc. (INM) - 8-K Summary InMed Pharmaceuticals has **regained compliance with Nasdaq's minimum bid price listing requirement** after the closing bid price of its common shares remained at or above $1.00 per share for 10 consecutive business days (May 19-June 2, 2026). The company had previously received a deficiency notice on March 27, 2026, when its stock fell below the $1.00 minimum for 30 consecutive trading days under Nasdaq Listing Rule 5550(a)(2), which governs continued listing on The Nasdaq Capital Market. With compliance now restored, Nasdaq has officially closed this matter. For investors, this development removes the immediate delisting threat and provides relief after the company successfully stabilized its share price above the regulatory threshold.

# Reborn Coffee, Inc. (REBN) – 8-K Summary Reborn Coffee announced the immediate resignation of Co-Chief Executive Officer Jay Kim on June 4, 2026, with Jung Jae Lim, who has served as Co-CEO since March 2026, assuming full CEO responsibilities. Lim brings over 20 years of experience in logistics and supply chain management, including expertise in large-scale operations and multi-node distribution networks. The change represents a leadership transition at the company (NASDAQ: REBN), though the company's operational continuity appears maintained through the promotion of an existing co-executive rather than an external appointment. No material financial or operational impacts are disclosed, and no family relationships exist between Lim and other company executives.

# VolitionRx Limited (VNRX) 8-K Summary VolitionRx Limited completed a securities offering on June 9, 2026, raising approximately $4.1 million in net proceeds by selling 2,960,000 common shares and 1,480,000 warrants at a combined price of $1.55 per share-warrant unit. The warrants are exercisable at $1.55 per share for five years and could generate an additional $2.3 million in gross proceeds if fully exercised. The company intends to use the net proceeds for research and product development, clinical studies, commercialization efforts, working capital, and repayment of existing secured convertible notes. This capital raise provides funding for VolitionRx's operations but also represents dilution to existing shareholders through the issuance of approximately 4.4 million new securities.

# Humacyte, Inc. (HUMA) 8-K Summary Humacyte announced positive Phase 3 clinical trial results (V012) for its acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis on June 10, 2026. The company disclosed this development through a press release and accompanying investor presentation, both filed as exhibits to this 8-K. While the filing does not provide specific efficacy or safety data within the document itself, the advancement of a lead product candidate through Phase 3 represents a material clinical milestone for this biotech company. Investors should review the attached press release and investor presentation for detailed trial results that will inform the probability of regulatory approval and commercial success of this therapeutic offering.

# Summary of Metagenomi Therapeutics 8-K Filing Metagenomi Therapeutics held its 2026 annual stockholder meeting on June 9, 2026, with a 50.8% quorum of shares outstanding, where shareholders elected two Class II directors (Juergen Eckhardt and Eric Bjerkholt) and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026. Both director elections passed comfortably, with Bjerkholt receiving particularly strong support at 94.5% approval despite 10.4 million broker non-votes. Additionally, board member Brian C. Thomas resigned effective immediately, though the company noted this was not due to any disagreement on operations or policies. These routine corporate governance matters carry minimal material impact on investors, as they reflect standard annual meeting procedures and leadership continuity rather than significant strategic changes or financial developments.

# 8-K Filing Summary: La Rosa Holdings Corp. La Rosa Holdings Corp. (NASDAQ: LRHC) completed the issuance of the remaining 250 shares of Series D Convertible Preferred Stock on June 10, 2026, following the filing of its 2025 Form 10-K on June 4, 2026. This second tranche brought total proceeds from the preferred stock offering to $500,000 ($250,000 received in May 2026 plus $250,000 from this closing), with each share priced at $1,000 under the Securities Purchase Agreement with an institutional investor. The Series D Preferred Stock carries conversion rights and other terms specified in the Certificate of Designation filed in May 2026. This represents a dilutive equity capital raise for the company that was contingent upon timely financial reporting compliance.

# TriLinc Global Impact Fund 8-K Summary As of May 31, 2026, TriLinc Global Impact Fund reported portfolio assets of approximately $283 million and has cumulatively funded $1.210 billion across 103 borrower companies globally, supporting over 43,500 permanent employees. The fund has recovered $905.7 million (75% of total invested) through repayments from trade finance, term loans, and other facilities, indicating a solid recovery rate on its impact investing activities. With a weighted average loan size of $10 million and short 0.4-year duration, the portfolio demonstrates active capital deployment and turnover. This routine portfolio update reflects ongoing operations of the impact lending fund with no material adverse events or changes in business status disclosed.

# Summary of Bio Green Med Solution, Inc. 8-K Filing Bio Green Med Solution, Inc. completed a private equity placement on June 10, 2026, raising $794,403 in gross proceeds by selling 1,103,338 shares of common stock at $0.72 per share to foreign accredited investors under Regulation S. The company has committed to filing a registration statement to enable the investors to resell their shares and must maintain the registration statement's effectiveness, bearing all associated registration expenses. The proceeds will be used for general corporate and operating purposes, representing a dilutive capital raise that slightly increases the company's cash position but introduces new shareholders into its cap table.

# NetCapital Inc. (NCPL) 8-K Summary NetCapital Inc. entered into a debt financing arrangement on June 5, 2026, issuing a $182,120 promissory note to Vanquish Funding Group Inc. for $157,000 in gross proceeds ($150,000 net), with net proceeds intended for general working capital. The note carries a 13% interest charge with five scheduled payments through March 2027, default interest at 22% per annum, and acceleration provisions that increase the repayment obligation to 150% or 200% of outstanding amounts upon default events. The note includes conversion rights allowing the lender to convert outstanding amounts into common stock at 65% of the lowest trading price during the preceding 20 trading days (with a $1.00 floor during the first six months), creating potential significant dilution if defaults occur. The financing includes restrictive covenants limiting asset sales and contains numerous default triggers including delisting, covenant breaches, and cross-defaults with other indebtedness, presenting meaningful liquidity and refinancing risks for shareholders.

# NIXXY, INC. 8-K Summary Nixxy, Inc. announced on June 9, 2026, a binding Letter of Intent (LOI) with Tachyon9 to create a NASDAQ-listed AI hyperscale infrastructure and energy platform, with a reported $1 billion infrastructure buildout backing the initiative. The filing indicates that the company is pivoting toward addressing what it identifies as AI's primary constraint: power infrastructure rather than computational chips. This represents a material strategic development that could significantly expand Nixxy's business scope and market positioning in the rapidly growing AI infrastructure sector. The transaction remains subject to definitive agreements and customary closing conditions, so investors should await further announcements regarding deal completion and financial terms.

# Summary of TOMI Environmental Solutions 8-K Filing TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announced that majority shareholders approved two significant corporate actions on June 4, 2026: (1) removal of a limitation restricting the company from issuing more than 19.99% of its common stock under a November 2025 purchase agreement with Hudson Global Ventures, LLC, and (2) authorization for the board to execute a reverse stock split at a ratio between 1-for-3 and 1-for-6 at any time within one year. These actions take effect 20 days after the definitive information statement is mailed to shareholders. The removal of the 19.99% issuance cap significantly increases Hudson Global Ventures' potential ownership stake and dilution risk for existing shareholders, while the reverse stock split authorization suggests the company may be addressing stock price concerns, possibly related to Nasdaq listing compliance.

# Sleep Number Corporation (SNBR) 8-K Summary Sleep Number Corporation appointed Colin M. Adams, Esq. to its Board of Directors effective June 4, 2026, expanding the board to 7 members with 6 independent directors under Nasdaq standards. Adams will receive compensation of $40,000 monthly plus additional fees for supplementary board activities. The filing contains no material transactions or conflicts of interest requiring disclosure, and there are no indications of operational or financial concerns affecting the company.

# Getty Images Holdings, Inc. – 8-K Summary On June 9, 2026, Getty Images received an adverse court ruling in a warrant dispute case filed in New York State Supreme Court. The court granted summary judgment to plaintiffs (Funicular Funds LP, et al.) regarding alleged breaches of warrant agreements dated August 4, 2020, with the potential liability reaching approximately $67.8 million plus pre-judgment interest—an amount the company had already reserved against in its May 2026 10-Q filing. The court conditionally granted summary judgment on additional warrants pending plaintiffs' submission of authorization letters by August 10, 2026, at which point judgment will be formally entered. This ruling represents a material adverse event that confirms the company's financial exposure and establishes binding liability for warrant-related damages, though the company had previously anticipated this outcome through its financial reserves.

# Summary of Fold Holdings, Inc. 8-K Filing On June 10, 2026, Fold Holdings, Inc. announced a significant deleveraging initiative, monetizing $45 million worth of bitcoin at an average price of approximately $71,000 per bitcoin and simultaneously eliminating $20 million of bitcoin-collateralized debt. This strategic move demonstrates the company's effort to reduce financial leverage while capitalizing on favorable cryptocurrency valuations. The transaction appears financially positive for investors, as it strengthens the balance sheet by reducing debt obligations without requiring equity dilution, though the disclosure provides limited detail on the company's remaining bitcoin holdings or future strategic direction.

# SEC 8-K Summary: Bio Green Med Solution, Inc. Bio Green Med Solution, Inc. (NASDAQ: BGMS) completed a private equity offering on June 10, 2026, raising $794,403 through the sale of 1,103,338 common shares to foreign accredited investors at $0.72 per share. The company simultaneously entered into a Registration Rights Agreement obligating it to file and maintain a resale registration statement for the shares, with the company bearing all registration expenses. The shares were offered under Regulation S, targeting non-U.S. persons outside the United States. While this capital infusion provides near-term liquidity for general corporate purposes, investors should note the dilution from 1.1 million new shares and the company's ongoing obligation to maintain effective resale registration, which could facilitate future selling pressure.

# AI Financial Corporation (AIFC) 8-K Summary AI Financial Corporation disclosed that approximately 3.3 billion of its 6.9 billion WLFI token holdings (valued at over $180 million) have become available for use as loan collateral, staking, and lending transactions, with the remaining tokens subject to a 12-month lock-up expiring August 12, 2026. Management believes this liquidity improvement materially mitigates the substantial doubt regarding the company's ability to continue as a going concern that was previously disclosed in its 10-Q filing, and states the company now has sufficient resources to fund operations for the next 12 months. The company's total WLFI holdings are valued at approximately $380 million based on current market prices of $0.055 per token. This development is significant for investors as it addresses critical liquidity concerns that had raised going concern issues, though the valuation and liquidity depend on the volatile crypto market and the company's ability to execute on its strategic initiatives.

# 8-K Summary: Zion Oil & Gas, Inc. Zion Oil & Gas announced the commencement of field operations for a planned sidetrack phase of its Megiddo-Jezreel #2 well in Israel, with the company having successfully re-entered the well and beginning the process of drilling out a temporary plug before proceeding with horizontal sidetrack drilling. The company's drilling rig has been re-certified and recommissioned in compliance with regulatory requirements and renamed JB-1 in honor of founder John Brown. This represents operational progress on the company's exploration activities in its 75,000-acre Megiddo Valleys License 434 concession in Israel, where management has emphasized safe and efficient execution of the approved work plan. The filing contains no material adverse developments or financial impacts disclosed; rather, it signals continued advancement of the company's onshore Israel exploration program, which could be viewed positively by investors following through on exploration plans.

# SEC 8-K Summary: Aeries Technology, Inc. Aeries Technology announced a one-for-eight share consolidation effective June 12, 2026, designed to increase the per-share stock price and maintain compliance with Nasdaq Capital Market's minimum bid price listing requirement. The consolidation will reduce outstanding Class A ordinary shares from approximately 45.9 million to 5.7 million, with proportionate adjustments made to stock options and equity awards. The company's stock will continue trading under the ticker "AERT" on Nasdaq Capital Market with a new CUSIP number, and the consolidation requires no shareholder action as it was previously authorized at the March 2026 Annual General Meeting. **Investor Impact:** While the consolidation mathematically increases the per-share price without changing the company's fundamental value, it signals that Aeries faces pressure to meet Nasdaq listing standards and suggests the stock has traded below the minimum bid price threshold. Shareholders should expect their share count to decrease proportionally, and those holding physical certificates must exchange them through Continental Stock Transfer & Trust Company.

# M3-Brigade Acquisition V Corp. - 8-K Summary M3-Brigade Acquisition V Corp. announced on June 10, 2026, that it has postponed its extraordinary general meeting of shareholders scheduled for June 15, 2026, to June 18, 2026, to allow shareholders additional time to consider the proposed business combination with ReserveOne, Inc. and to complete shareholder outreach efforts. Concurrently, the company extended the redemption deadline for Class A ordinary shareholders from June 11, 2026, to June 16, 2026 (two business days before the vote), providing Public Shareholders more time to exercise their redemption rights. The record date, meeting location, proposals, and board recommendations remain unchanged. This three-day postponement appears to be a tactical delay to maximize shareholder engagement and voting participation rather than a response to any material adverse development with the transaction.

# SEC 8-K Summary: DeFi Development Corp. (DFDV) On June 8, 2026, DeFi Development Corp. announced the resignation of Parker White, who served as Chief Operating Officer and Chief Investment Officer. Under the separation agreement, the Company will pay White $250,000 in cash over twelve months and accelerate vesting of 213,272 stock options, while also engaging him as a consultant at $8,333 monthly to oversee the transition of validator operations. This departure represents a significant leadership change at the emerging growth company, though the consulting arrangement suggests continuity on critical operational matters. The financial impact of approximately $100,000 annually ($250,000 severance plus consulting fees) plus the option acceleration is material to a smaller development-stage company, and investors should monitor how the loss of the COO/CIO affects the company's strategic direction and validator operations going forward.

# AIM ImmunoTech Inc. (AIM) – 8-K Summary On June 9, 2026, AIM ImmunoTech Inc.'s Board of Directors approved an amendment to the company's bylaws that changes the voting standard for shareholder proposals (excluding director elections). The new standard requires approval by a majority of votes **cast** on a proposal, excluding abstentions and broker non-votes, rather than the previous standard requiring a majority of shares **present and entitled to vote**. This is a shareholder-friendly governance change that lowers the threshold needed to pass most proposals, as it eliminates the counting of abstentions and non-votes against measures. The amendment became effective immediately on June 9, 2026 and has minimal material financial impact but reflects a governance modification that could make it easier for proposals to pass at future stockholder meetings.

# Purple Innovation, Inc. – 8-K Summary On June 9, 2026, Purple Innovation held its Annual Meeting of Stockholders, where all three proposals were approved. The company's eight-member board was re-elected with strong support, though director Adam Gray and Erika Serow received notably more opposition votes (9.1 million and 5.8 million votes against, respectively) compared to other directors. Advisory approval of executive compensation passed with approximately 88% support, while BDO USA, LLP was ratified as the independent auditor with over 95% approval. These results indicate stable governance with generally strong shareholder confidence, though the elevated opposition to two directors may warrant monitoring of investor concerns regarding specific board members or compensation practices.

# Lionheart Holdings 8-K Summary Lionheart Holdings, a special purpose acquisition company (SPAC), disclosed plans to offer non-redemption agreements to unaffiliated shareholders ahead of a June 15, 2026 extraordinary general meeting voting on an extension to complete an initial business combination through March 20, 2027. Under these agreements, shareholders who commit not to redeem their Class A ordinary shares would receive Class B ordinary shares from the Sponsor at an anticipated ratio of approximately one Class B share per five non-redeemed shares following the business combination closing. The company emphasized that while these agreements are not expected to increase approval likelihood for the extension, they would preserve more capital in the trust account for operations. The redemption deadline for Class A shareholders is set for June 11, 2026 at 5:00 p.m. Eastern time, and investors are urged to review the extension proxy statement and all related SEC filings before voting.

# MicroVision, Inc. - 8-K Summary On June 10, 2026, MicroVision, Inc. announced the signing of a Master Development Agreement with an initial Program Description dated June 1, 2026. The filing provides limited material details, with the company furnishing a press release (Exhibit 99.1) as the primary disclosure vehicle rather than detailed contractual terms. The agreement appears to represent a significant commercial collaboration, though specific financial terms, partner identity, and development scope are not disclosed in this 8-K itself. Investors should review the full press release for details on expected benefits, timeline, and revenue potential, as this filing contains standard forward-looking statement disclaimers regarding risks including partner performance, commercialization challenges, and competitive pressures in autonomous technology markets.

# SEC 8-K Summary: Blue Acquisition Corp. On June 9, 2026, Blue Acquisition Corp. (NASDAQ: BACC) announced the immediate resignation of Chief Executive Officer and director Ketan Seth due to family reasons, with no disputes cited. The company's board appointed David Bauer, the incumbent Chief Financial Officer, as interim CEO to assume operational leadership. This leadership transition occurred at a blank check company (SPAC) that is actively seeking a business combination opportunity. Investors should monitor for any potential impacts on deal timeline and strategy, given the change in top management during what is typically a critical acquisition phase for SPACs.

# Summary of Eureka Acquisition Corp 8-K Filing (June 8, 2026) Eureka Acquisition Corp extended its business combination deadline by one month (from June 3 to July 3, 2026) by paying a $150,000 extension fee funded by Marine Thinking Inc., the target company in the proposed merger. In connection with this extension, the Company issued a $150,000 unsecured promissory note to Marine Thinking that bears no interest and is due upon the earlier of business combination consummation or company termination. Marine Thinking has the right (but not obligation) to convert the note into private units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one-fifth of a warrant. The filing indicates the SPAC transaction remains in progress with shareholder approval materials expected following SEC effectiveness of the pending S-4 registration statement.

# SEC 8-K Summary: DeFi Development Corp. (DFDV) On June 8, 2026, Parker White resigned as Chief Operating Officer and Chief Investment Officer of DeFi Development Corp., a Nasdaq-listed cryptocurrency/blockchain company. Under the separation agreement, White will receive $250,000 in cash payments over twelve months plus acceleration of 213,272 unvested stock options, and will serve as a consultant at $8,333 monthly for operational transition matters. This departure removes a key executive responsible for operations and investment strategy, though the company is mitigating disruption through White's continued involvement in a consulting capacity. Investors should monitor whether this leadership transition affects the company's validator operations and strategic direction going forward.

# SEC 8-K Filing Summary: Mountain Lake Acquisition Corp. Mountain Lake Acquisition Corp. (NASDAQ: MLAC) announced on June 10, 2026, that it has postponed its extraordinary general meeting of shareholders from an unspecified earlier date to June 16, 2026, to allow additional time to complete its previously approved business combination with Avalanche Treasury Corporation. The postponement extends the deadline for shareholders to vote on an extension of the company's deadline to consummate the business combination from June 16, 2026 to September 16, 2026. All other meeting terms—location, record date, redemption deadline, and voting proposals—remain unchanged. This delay provides the SPAC with a three-month extension to finalize the merger transaction, which was already shareholder-approved on June 4, 2026, and suggests potential complications or extended negotiations in completing the deal closure.

# Ribbon Acquisition Corp. 8-K Summary Ribbon Acquisition Corp. (NASDAQ: RIBB), a special purpose acquisition company (SPAC), reported two material developments on June 10, 2026. First, the company deposited $125,000 into its trust account to extend its business combination deadline by one month, from June 15, 2026 to July 15, 2026, providing additional time to identify and complete an acquisition target. Second, the company resolved a Nasdaq listing compliance issue by paying outstanding fees and regaining compliance with Nasdaq Listing Rule 5250(f), eliminating delisting risk. **Investor Impact:** The extension demonstrates the company is actively working toward a business combination but has not yet secured a target deal. The resolution of the Nasdaq compliance violation is positive, as it removes near-term delisting risk. However, investors should note the tight timeline—the company now has approximately one month to announce or complete a business combination before its extended deadline expires, creating execution pressure for management.

# Summary of enGene Therapeutics Inc. 8-K Filing enGene Therapeutics Inc. held its 2026 Annual General Meeting on June 9, 2026, with strong shareholder participation at 83.89% of outstanding shares. All four director nominees—Philip Astley-Sparke, Ronald H.W. Cooper, Dr. William Grossman, and Michael Heffernan—were elected with overwhelming support (ranging from 99.98% to 99.99% approval), indicating strong investor confidence in the board. The company's auditor was reappointed with similarly robust approval (99.97% of votes cast). This routine governance event reflects healthy shareholder engagement and no material changes to company operations or investor risk profile.

# EBR Systems, Inc. – 8-K Summary EBR Systems completed a A$150 million capital raise on the Australian Securities Exchange through a combination of institutional placement and entitlement offering, issuing approximately 394.7 million CHESS Depository Interests (CDIs) at A$0.38 per CDI—representing a 19.1% discount to the prior closing price. The raise comprises an institutional placement of A$64.4 million (with A$35 million tranche subject to shareholder approval) and a 1-for-2 pro rata entitlement offer of approximately A$85.6 million to existing shareholders in Australia and New Zealand. Settlement of the institutional components is expected June 11, 2026, while the shareholder-approved tranche and retail entitlement offer will follow subsequently. This significant dilutive capital raise signals the company is addressing liquidity needs, likely to fund operations or growth initiatives, and the substantial discount reflects typical capital raise dynamics but increases near-term downward pressure on the share price for existing investors.

# SEC 8-K Summary: Earth Science Tech, Inc. Earth Science Tech, Inc. (ticker: ETST) filed a Form 8-K on June 10, 2026, disclosing the issuance of its annual shareholder letter for the fiscal year ended March 31, 2026. The filing is a standard Regulation FD disclosure containing minimal material information, with the substantive content relegated to an attached press release. As the company trades on the Over-the-Counter Bulletin Board (OTC), this announcement appears routine and does not indicate significant corporate events, strategic changes, or financial material announcements. Investors should review the full press release (Exhibit 99.1) for actual financial performance and business updates, as the 8-K itself provides no operational or financial details.

# Summary of Pantages Capital Acquisition Corporation 8-K Filing Pantages Capital Acquisition Corporation, a blank-check SPAC, obtained shareholder approval on June 3, 2026 to extend its business combination deadline by up to 12 months (from June 6, 2026 to June 6, 2027) on a month-by-month basis. The company amended both its articles of association and investment trust agreement to facilitate these extensions, with shareholders required to fund each one-month extension at $0.033 per public share (capped at $60,000 per extension). The Extension Amendment Proposal and Trust Agreement Amendment Proposal were both approved with approximately 70% shareholder support (6.7 million votes for versus 2.8 million against out of 9.6 million votes cast). For investors, this provides additional time for management to locate a business combination target but extends uncertainty; shareholders dissatisfied with the extension can redeem their shares before the extended deadline.

# Nuwellis, Inc. (NUWE) - 8-K Summary Nuwellis, Inc. completed a registered public offering on June 8, 2026, raising approximately $6.0 million in gross proceeds (before placement agent fees and offering expenses). The offering included pre-funded warrants that were exercised, resulting in 12.75 million shares of common stock outstanding as of June 9, 2026. This capital raise provides the medical device company with liquidity to support operations, though the significant dilution from the offering and warrant exercises may pressure existing shareholders. Investors should monitor the company's use of proceeds and cash burn rate, particularly given the capital raise size relative to typical biomedical company operational costs.

# Summary of Fold Holdings, Inc. 8-K Filing Fold Holdings, Inc. announced on June 10, 2026, that it has monetized $45 million of bitcoin at an average price of approximately $71,000 per bitcoin and used proceeds to eliminate $20 million of bitcoin-collateralized debt. This represents a strategic deleveraging action that reduces the company's financial obligations while realizing gains on a portion of its digital asset holdings. The transaction demonstrates management's decision to de-risk the balance sheet by converting volatile cryptocurrency assets into debt reduction, which should improve the company's financial stability and reduce leverage ratios going forward.

# Mobix Labs, Inc. (MOBX) - 8-K Filing Summary Mobix Labs is actively pursuing a non-binding acquisition of Vision Aerial, Inc., though no definitive agreement has been reached and the transaction remains subject to due diligence, financing availability, and stockholder/regulatory approvals. The company is also proceeding with a Kips Bay Select LP financing transaction, expecting to file a resale registration statement for approximately 4.54 million shares and anticipating a stockholder meeting in July 2026 to approve the Kips issuance, charter amendments, and expanded equity capacity for future acquisitions and fundraising. Additionally, Mobix recently settled two lawsuits and paid down approximately $3.74 million in debt, reducing outstanding liabilities. However, the company plans to raise significant additional capital through unspecified financing transactions that could involve equity dilution, and all major corporate initiatives depend on stockholder approval—failure to obtain required votes could materially impair the company's ability to complete acquisitions or access financing. **Investor Impact:** Existing shareholders face near-term dilution from the Kips issuance and future financings, while execution risk remains high given the preliminary status of the Vision Aerial deal and dependence on stockholder votes and SEC clearance.

# Summary of Silver Bull Resources, Inc. 8-K Filing (June 1, 2026) Silver Bull Resources announced that its international arbitration claim against Mexico has been completely dismissed by the World Bank's ICSID tribunal, which ruled it lacked jurisdiction and/or the claim was time-barred. The company has been ordered to pay approximately $998,000 in Mexico's legal costs, representing a significant financial loss. The arbitration stemmed from Mexico's expropriation and blockade of Silver Bull's Sierra Mojada silver property. Management is evaluating whether to pursue annulment proceedings (which would take 18-36 months if filed within 120 days) and exploring alternative strategic options, including seeking resolution of the ongoing blockade or identifying new exploration projects. This dismissal eliminates a major potential asset recovery pathway for investors and signals increased financial strain on the company.

# SEC 8-K Summary: BYNORDIC ACQUISITION CORPORATION BYNO, a blank-check company trading on OTC Pink Limited Market, extended its business combination deadline by one month to July 12, 2026, by depositing $17,470 into its trust account on June 9, 2026. This extension was previously authorized by the board and stockholders and represents the company's effort to secure additional time to identify and complete a merger or acquisition target before liquidation would otherwise occur. The extension mechanism demonstrates BYNO's continued viability as a going concern, though the tight deadline suggests the company remains under pressure to complete its transaction. **Investor Impact:** Shareholders retain potential upside if a business combination is announced soon, but the compressed timeline increases liquidation risk if no deal closes by July 12, 2026. Trust account funds continue to be available for the transaction and operating expenses, but investors should monitor announcements closely given the near-term deadline.

# Summary of Crown PropTech Acquisitions 8-K Filing Crown PropTech Acquisitions (a SPAC) and Mkango Rare Earths Limited are conducting investor meetings to raise private capital through equity, debt, and convertible securities in support of their previously announced business combination. The companies have filed a Form F-4 registration statement with the SEC and plan to mail a definitive proxy statement/prospectus to shareholders for voting on the proposed merger. This financing activity is intended to fund the advancement of Mkango's rare earths projects, including potential development financing from the U.S. Development Finance Corporation (DFC). **Investor Impact:** The private capital raise suggests the SPAC merger is progressing toward completion, but investors should note that the transaction remains subject to shareholder approval and regulatory clearance. The reliance on additional financing (including potential DFC funding) indicates capital intensity of Mkango's operations, which carries execution risk. Shareholders should review the forthcoming proxy statement/prospectus for detailed terms, use of proceeds, and potential dilution from the financing activities.

# Summary of Humacyte, Inc. 8-K Filing Humacyte, Inc. announced on June 10, 2026, the presentation of Phase 3 clinical trial results for its acellular tissue engineered vessel (ATEV) designed for arteriovenous access in female patients with end-stage renal disease requiring hemodialysis. The company released a press release and investor presentation detailing these trial outcomes. This clinical milestone is significant for investors as positive Phase 3 data could support potential regulatory approval and commercialization of the company's lead product candidate. The specific trial results and their clinical implications are contained in the exhibits filed with this 8-K, which will be relevant to the company's future market prospects and stock valuation.

# NetCapital Inc. 8-K Summary NetCapital Inc. entered into a Securities Purchase Agreement on June 5, 2026, issuing a $182,120 promissory note to Vanquish Funding Group Inc. for $157,000 in gross proceeds ($150,000 net), reflecting a 13.8% original issue discount. The note matures on March 30, 2027, with payments structured as one lump sum of $71,250 in November 2026 and four equal installments of $33,636.25, plus a one-time 13% interest charge totaling $205,795 in aggregate payments. The company intends to use proceeds for general working capital purposes. **Investor Impact**: The debt carries significant downside risks, including a 22% default interest rate, immediate acceleration at 150% of outstanding obligations upon default (increasing to 200% if conversion share obligations also default), and broad event-of-default triggers including delisting, covenant breaches, and cross-defaults. The convertible feature at 65% of lowest trading price over 20 days (floored at $1.00 for six months) creates substantial dilution risk, and restrictive covenants limit asset dispositions, signaling financial distress and elevated refinancing risk for shareholders.

# Summary of Aeries Technology, Inc. 8-K Filing Aeries Technology, Inc. announced a one-for-eight share consolidation effective June 12, 2026, approved by its Board to increase the per-share trading price and maintain compliance with Nasdaq Capital Market's minimum bid price listing requirement. The consolidation will reduce outstanding Class A ordinary shares from approximately 45.9 million to 5.7 million, with no fractional shares issued and automatic account crediting for shareholders. Proportionate adjustments will be made to all outstanding stock options and equity awards, and the company's ticker symbol (AERT) will remain unchanged, though a new CUSIP number will apply. **Investor Impact:** While the consolidation does not change the company's underlying value or shareholder ownership percentages, it addresses a potential delisting risk on Nasdaq and may help restore stock price stability. However, investors should note this is a defensive measure suggesting the company's stock price had fallen below Nasdaq's minimum bid price threshold, which could indicate broader operational or market challenges.

# Summary of ADITXT, INC. Form 8-K Filing On June 10, 2026, Aditxt, Inc.'s subsidiary Ignite Proteomics, LLC entered into a Business Combination Agreement with Copley Acquisition Corp (a SPAC) and related parties to merge Ignite with the SPAC, resulting in a newly public company called Ignite Proteomics Holdings, Inc. Ignite's shareholders will receive $150 million in consideration (valued at $10 per share, translating to 15 million shares), plus the SPAC sponsor will receive an additional $4 million, making this a $154 million transaction. Following the merger, Ignite will become a wholly-owned subsidiary of the public Pubco entity, and Aditxt shareholders will own a portion of the merged company. The deal notably includes no post-closing survival of representations and warranties, meaning shareholders have no recourse for undisclosed liabilities after closing, which increases post-transaction risk for investors in the combined entity.

# SEC 8-K Summary: Purebase Corporation Purebase Corporation announced the appointment of Dr. Amy T. Clemens as Chief Financial Officer effective June 4, 2026, marking her return to the role after previously serving in the position from February 2014 to April 2016. Dr. Clemens, age 69, brings experience as co-owner and CFO/COO of OPTEC Solutions LLC, a government contractor, since January 2008. The appointment includes no special arrangements or related-party conflicts, though Dr. Clemens did receive $25,000 for administrative services provided to the company between February and April 2026. This leadership change is material as it fills the CFO position with an experienced executive who previously navigated the company's financial operations, potentially providing continuity and stability for investors.

# Summary of P3 Health Partners Inc. 8-K Filing (June 9, 2026) P3 Health Partners held its 2026 Annual Meeting of Stockholders on June 9, 2026, where shareholders approved all four proposals with strong majorities. The key actions include: (1) election of three Class II directors (Amir Bacchus, M.D.; Mark Thierer; and Lawrence B. Leisure) through 2029, (2) ratification of BDO USA, P.C. as the independent auditor for 2026, (3) advisory approval of named executive officer compensation, and (4) approval to issue up to 3,341,130 shares of Class A common stock upon exercise of warrants held by VBC Growth SPV 5, LLC under Nasdaq Rule 5635(d). With minimal opposition across all proposals, the filing indicates stable governance and shareholder support for management's strategic direction, though the warrant dilution could impact existing shareholders' ownership percentages.

# M2I Global, Inc. – 8-K Summary On June 4, 2026, M2i Global received a termination notice from Volato Group, Inc. purporting to terminate their merger agreement dated July 28, 2025, citing alleged grounds under Section 10.1 of the agreement. M2i Global disputes the termination, contends it has complied with all material obligations, and rejects the notice as without merit, reserving all rights and remedies. The company intends to vigorously pursue legal action to enforce its contractual rights, including seeking damages and/or equitable relief, though the ultimate outcome remains uncertain. This represents a significant negative development for investors, as the planned merger is now in dispute and creates substantial uncertainty regarding M2i Global's strategic direction, financial condition, and potential litigation expenses.

# Summary of KIDZ AI Inc. 8-K Filing On June 10, 2026, KIDZ AI Inc. held its annual stockholder meeting and obtained approval for five significant proposals that expand the company's financial and operational flexibility. The most material items include: (1) increasing authorized Class B common stock from an unspecified amount to 2.5 billion shares; (2) approving issuance of Class B shares to Solana Growth Ventures LLC under a December 29, 2025 exchange agreement; (3) authorizing a reverse stock split at a ratio between 1-for-2 and 1-for-50 to be determined by the board; and (4) approving the sale of up to 500,000 Class A shares to CEO Hui Luo at 150% of market price. All five proposals passed with strong shareholder support (77-88% approval rates). **Investor Impact:** The reverse stock split authorization and massive increase in authorized shares signal potential dilution and stock price volatility, while the related-party share issuance to the CEO raises governance concerns. The exchange with Solana Growth Ventures suggests potential business development activity. These approvals provide management with broad discretionary power that could significantly impact existing shareholders' ownership percentages and equity value.

# Summary of CID Holdco, Inc. Form 8-K Filing CID Holdco, Inc. (NASDAQ: DAIC) announced on June 10, 2026, that it has entered into two non-binding letters of intent as part of its strategic alternatives review: a proposed $5.0 million convertible preferred stock investment from an investor, and a separate agreement to sell a portion of its operating business for approximately $6.0 million in cash plus the assumption of up to $3.0 million in liabilities. The investor may also provide additional funding for value-creating initiatives. These transactions are non-binding and subject to multiple conditions, including definitive agreement execution, stockholder approval, and continued Nasdaq listing compliance. For investors, this signals the company is pursuing capital restructuring and potential business divestiture, though completion remains uncertain as the letters of intent are preliminary agreements that may not result in final transactions.

# SEC 8-K Summary: Taboola.com Ltd. On June 9, 2026, Taboola.com Ltd. held its Annual General Meeting of Shareholders and obtained shareholder approval for all five proposals presented, including the re-election of two Class II directors, an advisory vote on executive compensation, and the approval of the company's compensation policies and CEO compensation terms. Additionally, shareholders voted to re-appoint Kost, Forer, Gabbay & Kasierer (an EY member firm) as the independent registered public accounting firm for 2026. All proposals received majority support, with the strongest backing for the auditor re-appointment (168.6 million votes in favor) and the CEO compensation approval (111.0 million votes in favor). This routine governance event presents no material adverse impact to investors and reflects standard shareholder approval processes for executive compensation and audit oversight at the NASDAQ-listed company.

# Summary of Nixxy, Inc. 8-K Filing On June 9, 2026, Nixxy, Inc. (NASDAQ: NIXX) announced a binding Letter of Intent (LOI) with Tachyon9 to create a NASDAQ-listed AI hyperscale infrastructure and energy platform, with plans to support a $1 billion infrastructure buildout. The announcement reflects Nixxy's strategic pivot to address what the company identifies as power availability—rather than chip availability—as the primary constraint limiting AI infrastructure expansion. This potential combination positions Nixxy to operate in the growing intersection of AI infrastructure and energy solutions, a high-demand sector. Investors should monitor the transaction's progress, as LOI agreements are non-binding preliminary commitments and may not result in a completed merger or combination. The actual financial impact and terms of any final agreement remain to be disclosed in future filings.

# Visium Technologies 8-K Summary On June 8, 2026, Visium Technologies terminated its material incubation arrangement with ConnexUS AI, determining the initiative had failed to achieve its objectives and was no longer in the company's best interest. Under the Mutual Release, Settlement, and Termination Agreement, Visium relinquished all claims to the ATHENA platform intellectual property (which remains wholly owned by ConnexUS), while ConnexUS waived all payment obligations including the $190,000 in prior incubation funding, effectively writing off this investment as a non-refundable expense. Additionally, Cheddi Rai resigned from all officer, director, and advisory positions at Visium, and the company's board was reduced to three members: Paul R. Taylor (Chairman/CEO), Mark Lucky (CFO), and David Pierce (Independent Director). The termination provides a "clean break" with comprehensive mutual releases protecting both parties from future claims, though it signals that Visium's AI platform development strategy with ConnexUS failed to deliver commercial viability and strategic alignment. **Investor Impact:** The $190,000 sunk cost loss and abandonment of the ATHENA platform acquisition represent a strategic setback, but the mutual release and executive departure may provide management clarity and refocus. Investors should monitor whether Visium can successfully pivot its core RAG/agentic AI initiatives independently or pursue alternative partnerships.

# Wheels Up Experience Inc. (UP) - 8-K Summary Wheels Up stockholders approved a significant expansion of its equity incentive plan at the June 9, 2026 annual meeting, increasing available shares under the 2021 Long-Term Incentive Plan by 3.75 million shares (75 million pre-reverse split) to a total of 6.76 million shares, with the plan extended through March 31, 2036. The approval came with strong support (99.4% voting in favor) from shareholders representing 92.6% of outstanding shares, reflecting robust quorum participation. Additionally, stockholders reelected four Class II directors and approved advisory votes on executive compensation and the appointment of Grant Thornton LLP as the independent auditor. The expanded share pool will provide management with increased flexibility for equity-based compensation, potentially diluting existing shareholders but signaling management confidence in the company's long-term strategy post-reverse stock split.

# Summary of Figure Technology Solutions, Inc. Form 8-K Filing Figure Technology Solutions, Inc. announced on June 10, 2026, that it has entered into a definitive merger agreement to acquire Kiavi, Inc., a fintech company, for approximately $532.4 million in cash (subject to customary adjustments). The transaction is structured as a merger between Figure's subsidiary and Kiavi, with Kiavi surviving as a wholly owned subsidiary of Figure. Closing is expected by November 30, 2026, subject to customary conditions including Hart-Scott-Rodino antitrust clearance, regulatory approvals, and Kiavi shareholder consent. Figure has secured a $600 million bridge financing commitment from Bank of America and Barclays to fund the acquisition, though the company intends to finance the deal primarily through capital markets transactions. The merger agreement includes a $25 million termination fee payable by Figure under certain specified conditions, and mutual termination rights exist if closing does not occur by the End Date or if regulatory/material conditions are not satisfied. **Investor Impact:** This represents a significant strategic acquisition for Figure, but investors should monitor execution risks including regulatory approval timelines, market conditions for financing, and the ability to close by year-end 2026.

# NEWS CORPORATION 8-K SUMMARY News Corporation filed this 8-K on June 9, 2026, to disclose information regarding its ongoing stock repurchase program authorized to acquire up to $1 billion in aggregate of Class A and Class B common stock. The filing is primarily a procedural disclosure of repurchase activity reported to the Australian Securities Exchange (ASX) on a daily basis, with detailed transaction information attached as exhibits. While the company reiterates its intent to repurchase shares opportunistically, the filing includes standard forward-looking statement disclaimers noting that actual repurchase activity may vary based on stock price, market conditions, and other factors. This is a routine regulatory filing with minimal material impact on investors, serving primarily to satisfy ASX transparency requirements.